Key facts
- It has raised $40.0M; the latest was Seed Round ($40.0M) in Dec 2025.
- Notable investors include Club degli investitori, Nova Capital (Italy).
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Juniper Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Juniper Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Juniper Biosciences
Developer of therapeutic and diagnostic agents intended for precision healthcare and disease management purposes. The company advances a pipeline of radiopharmaceutical solutions that integrate radioisotopes with high-specificity ligands, supported by expertise in drug development, clinical validation, and patient-centered design, offering early disease detection, targeted treatment delivery, minimized side effects, and improved therapeutic outcomes, enabling healthcare providers, research institutions, and patients to access innovative approaches that address unmet medical needs in oncology and other conditions while ensuring quality, safety, and broader accessibility across clinical practice.
- Sector
- Healthcare
- HQ
- Bridgewater, NJ, United States
- Founded
- 2025
- Website
- juniperbiosci.com/
- Ownership
- Privately Held (backing)
Juniper Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Juniper Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Juniper Biosciences in its N-PORT filings yet. We sweep new filings monthly.